secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037994
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections
--------------------------------------------------------------------------------

- Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).
- Cash, equivalents & investments $477M at June 30, 2023; includes $93.6M net from June offering; runway to mid-2026.
- Ziftomenib in NPM1-mutant AML: CR rate 35% at 600 mg RP2D; registration-directed trial (85 pts) enrollment ahead of projections.
- Combination study KOMET-007 (ziftomenib + ven/aza or 7+3) now dosing patients; preliminary data expected Q4 2023 or Q1 2024.
- Next-gen FTI KO-2806 Phase 1 FIT-001 trial to begin dosing in H2 2023; tipifarnib+alpelisib in HNSCC at highest planned dose cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/0000950170-23-037994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/kura-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer